Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Artisan Global Discovery Jason White | “Insmed is a commercial-stage biotechnology company focused on pulmonary diseases. BRINSUPRI® continued its rapid launch, with robust patient uptake and encouraging third-party data. While Q1 sales came in modestly below elevated investor expectations, reflecting concerns around discontinuation rates, continuation on therapy and typical early-year seasonality, the underlying launch trajectory remains encouraging. We continue to view BRINSUPRI® as a significant long-term opportunity. Our due diligence suggests the therapy remains well tolerated and is on track to achieve blockbuster-level sales. We trimmed the position during the quarter.” | NEUTRAL | Q2 2026 Jul 29, 2026 | View Pitch |
Baron Health Care Fund Neal Kaufman | “Insmed Incorporated is a biotechnology company with three lead pulmonology assets that we believe can collectively generate more than $8 billion in peak sales. We are particularly excited about Brinsupri for non-cystic fibrosis bronchiectasis, which we view as a $5 billion-plus opportunity. Despite what we believe has been a strong start to the launch, shares fell after first-quarter Brinsupri sales missed expectations as investors focused on early signs of higher treatment discontinuations. Insmed's exit from the Nasdaq-100 Index created additional technical selling pressure. Long term, we continue to view Brinsupri as an important treatment option for the 500,000-plus bronchiectasis patients in the U.S. We remain bullish on the portfolio's long-term fundamentals, including the opportunity for treprostinil palmitil inhalation powder (TPIP), which is being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Compared to existing inhaled prostanoids that require four daily treatments, once-daily TPIP is more convenient and can be dosed at significantly higher levels, potentially resulting in meaningfully better efficacy.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Insmed is a commercial-stage biotechnology company focused on pulmonary diseases. Brinsupri® continued its rapid launch. While patient uptake remains strong, Q1 sales fell short of elevated investor expectations, raising questions about discontinuation rates and putting downward pressure on the stock. However, we continue to view Brinsupri® as a meaningful long-term opportunity. Our due diligence suggests the drug remains well tolerated and is on track for blockbuster-level sales.” | NEUTRAL | Q2 2026 Jul 21, 2026 | View Pitch |
Alger Mid Cap Focus Fund Amy Zhang | “Insmed is a commercial-stage biopharmaceutical company focused on respiratory, inflammatory, pulmonary, and rare disease treatments, with an approved portfolio that includes Brinsupri and Arikayce. The company's opportunity is tied to expanding adoption of its commercial products while advancing a pipeline aimed at areas of meaningful unmet medical need. During the quarter, shares detracted from performance despite headline results that were generally better than expected, as investors focused on early launch dynamics for Brinsupri. Concerns centered on patient additions, discontinuation rates, and compliance trends, which raised questions about the quality and durability of the launch. While these issues pressured the stock, management has begun providing greater detail around launch dynamics, and we believe improved execution and additional data could help restore investor confidence over time.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Artisan Global Discovery Jason White | “Insmed is a biotechnology company focused on pulmonary diseases. Its lead product, ARIKAYCE®, continues to perform well, with management raising full-year revenue guidance following 22% YoY growth. The company also reported a strong launch for Brinsupri™ (brensocatib), the first approved therapy for non-cystic fibrosis bronchiectasis, generating $28 million in initial sales with more than 2,500 patients and 1,700 prescribers. We remain encouraged by Insmed's execution and believe Brinsupri™ is likely to drive a substantial profit cycle in the coming quarters and years. BSD Analysis: Insmed is a high-growth biopharmaceutical company that is successfully transitioning from a single-product firm into a multi-blockbuster powerhouse. The primary catalyst for 2026 is the rapid commercial uptake of Brensocatib, following its landmark approval for the treatment of bronchiectasis, a market with significant unmet need and no existing approved therapies. Additionally, the company's flagship product, Arikayce, continues to see strong double-digit revenue growth as it expands into the first-line treatment setting for MAC lung disease. Insmed's robust clinical pipeline, which includes promising gene therapy candidates and treatments for rare respiratory conditions, provides a long-term growth floor beyond its current commercial portfolio. For 2026, the company is expected to move closer to overall profitability as rising revenues from its new launches begin to outpace its R&D and commercialization expenses. With a focused management team and multiple high-impact readouts on the horizon, Insmed remains a top-tier pick in the mid-cap biotech space.” | BULL | Q4 2025 Jan 27, 2026 | View Pitch |
Artisan Partners Small Cap Fund Jay Warner | “Insmed is a biotechnology company focused on pulmonary diseases. We exited our position during the quarter due to market cap considerations, though the stock remained a top performer. Its strength was driven by the successful launch of Brinsupri™ (brensocatib), the first approved therapy for non-cystic fibrosis bronchiectasis, which generated $28 million in initial sales from roughly 2,500 patients and 1,700 prescribers, along with a robust pipeline of additional potential therapies. BSD Analysis: Insmed is a rare-disease biotech built around deep specialization rather than pipeline sprawl. Its lead franchise generates cash that reduces dependence on capital markets. Expansion into adjacent indications increases lifetime value without reinventing the model. Clinical execution, not science, is now the main swing factor. Investors worry about concentration risk and miss operating leverage. Regulatory clarity supports steady adoption. Pipeline optionality exists without existential burn risk. This is biotech behaving like an operator. Progress compounds slowly, then suddenly.” | BULL | Q4 2025 Jan 21, 2026 | View Pitch |
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Insmed is a biotechnology company focused on pulmonary diseases. Its lead product, ARIKAYCE®, continues to perform well, with management raising full-year revenue guidance following 22% YoY growth. The company also reported a strong launch for Brinsupri™ (brensocatib), the first approved therapy for non-cystic fibrosis bronchiectasis, generating $28 million in initial sales with more than 2,500 patients and 1,700 prescribers. We remain encouraged by Insmed's execution and believe Brinsupri™ is likely to drive a substantial profit cycle in the coming quarters and years. BSD Analysis: Insmed is a rare-disease biotech built around deep focus rather than pipeline sprawl. Its lead franchise generates cash, reducing dependence on capital markets. Expansion into adjacent indications increases lifetime value without reinventing the model. Clinical execution, not science, is now the main swing factor. Investors worry about concentration risk, but specialization is the advantage here. Regulatory clarity and trial outcomes will drive sentiment shifts. Optionality exists without existential burn risk. This is biotech behaving more like an operator than a lottery ticket. Progress compounds slowly, then suddenly.” | BULL | Q4 2025 Jan 15, 2026 | View Pitch |
Artisan Partners Small Cap Fund Jay Warner | “Insmed is a commercial-stage biotech company focused on serious pulmonary diseases. Its lead product is ARIKAYCE®, an inhaled antibiotic that treats lung infections unresponsive to standard therapies. The company recently received FDA approval for Brinsupri™, the first once-daily oral treatment for non-cystic fibrosis bronchiectasis—a chronic and progressive lung condition with limited treatment options. With over one million diagnosed patients across the US, Europe and Japan, Brinsupri™ addresses a major unmet need, and we expect rapid adoption. In our view, Insmed also has a promising pipeline, including a third de-risked drug candidate with multibillion-dollar potential. Given the company's increasing market capitalization, we began to pare back our CropSM position. BSD Analysis: The pitch emphasizes a validated commercial platform with a new blockbuster indication (NCFBE). With expanding TAM and pipeline optionality, revenue acceleration should drive operating leverage; valuation upside depends on execution.” | BULL | Q3 2025 Oct 20, 2025 | View Pitch |
Orbis Global Equity Fund Brent Jackson | “The newest addition to our biotech holdings, Insmed, has achieved a major milestone with the recent FDA approval of brensocatib (brand name: BRINSUPRI) for bronchiectasis—with a clean label and strong pricing. This marks the first approved therapeutic option for patients with this chronic lung disease, whose quality-of-life burden is comparable to that of chronic obstructive pulmonary disease. We anticipate a rapid adoption curve that should push the company toward sustained profitability. The attraction, however, goes well beyond a single drug. The second pipeline asset, TPIP, has now achieved key clinical validation in pulmonary arterial hypertension as well as idiopathic pulmonary fibrosis, reinforcing its potential as a transformative therapy for patients suffering from deadly lung diseases. Combined with its already approved ARIKAYCE for Mycobacterium avium complex lung disease, the launch of brensocatib and the progress of TPIP are helping Insmed build a powerful respiratory disease franchise—a disease-focused strategy that has proven lucrative for other biotech leaders. Despite a recent rally following BRINSUPRI approval and TPIP clinical readouts, shares remain well below our estimate of their intrinsic value, leaving substantial room for multi-year appreciation. Insmed is led by its long-time CEO Will Lewis, who took the helm when the company's market capitalisation was under $100 million (now $30 billion). During his tenure, the company has created significant shareholder value through disciplined R&D bets. A continuation of this strategy should lead to further value creation that the market is not pricing into the shares. BSD Analysis: Insmed's brensocatib sets up one of biotech's biggest potential catalysts, attacking a massive unmet need in bronchiectasis with credible early data. The TAM is huge, and commercial ramp could be explosive if Phase 3 hits. Cash burn is high, but that's the price of swinging for real clinical impact. Bears fixate on dilution risk, but the upside dwarfs the financing concerns. Insmed has a diversified pipeline providing multiple shots on goal. The stock trades with heavy skepticism — ideal for a catalyst-driven name. High conviction, high volatility, real upside.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Insmed's FDA approval for Brinsupri™, the first once-daily oral treatment for non-cystic fibrosis bronchiectasis, marks a major milestone. With a large patient base in the U.S., Europe, and Japan, the company addresses a substantial unmet need. Insmed's pipeline includes additional de-risked assets with multibillion-dollar potential. BSD Analysis: Insmed is approaching a major inflection point, with brensocatib's Phase 3 data setting the stage for a potential blockbuster in neutrophil-driven lung disease. The company's pipeline beyond NCFB is underappreciated, offering significant optionality across rare pulmonary and inflammatory conditions. Operating discipline has improved, and the company maintains a solid cash runway into pivotal milestones. Investor skepticism lingers due to biotech volatility, but the risk-reward setup into commercial transition looks compelling. If approval plays out as expected, Insmed could scale rapidly into a high-margin rare-disease franchise.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
